Fig. 2From: Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevanceComparison of OS and DFS between patients with low or high gene expression with statistical significance in univariate analysis. a, b The median OS and DFS of patients with low or high MECOM expression were 30 ± 4.7 months versus 11 ± 1.8 months (P < 0.001), and 39 ± 8.1 months versus 14 ± 3.8 months (P = 0.017), respectively. c, d The median OS and DFS of patients with low or high MEIS1 expression were 34 ± 5.3 months versus 11.5 ± 1.7 months (P < 0.001), and 39 ± 8.7 months versus 14.5 ± 4.1 months (P = 0.016), respectively. e, f The median OS and DFS of patients with low or high SPI1 expression were 25 ± 5.4 months versus 14 ± 2.1 months (P = 0.008), and 36 ± 7.7 months versus 21 ± 5.3 months (P = 0.039), respectively. g, h The median OS and DFS of patients with low or high WT1 expression were 22 ± 4.2 months versus 15 ± 2.3 months (P = 0.096) and 39 ± 14.4 months versus 20 ± 5.9 months (P = 0.098), respectively. i, j Patients with low expression of both MECOM and MEIS1 were compared to those with either or both high expression of MECOM and MEIS1. The median OS were 56.5 ± 17.5, 14 ± 2.6 and 8 ± 2.2 months (P < 0.001). The median DFS were 46 ± 8.2, 27.5 ± 7.9 and 12 ± 1.7 months (P = 0.013). The hazard ratios (HR) of high MECOM or MEIS1 for OS and DFS were 2.076 (95% CI 1.455–2.962) and 1.379 (95% CI 0.893–2.131), respectively, while the HR of High MECOM and High MEIS1 were 3.040 (95% CI 2.088–4.427) and 2.024 (95% CI 1.265–3.238), respectively. k, l The OS and DFS were compared in a subgroup of patients with low expression of both MECOM and MEIS1. The median OS and DFS of patients with low or high WT1 expression were NR versus 18 ± 2.4 months (P = 0.002), and 77 ± 32.7 months versus 18 ± 4.5 months (P = 0.002), respectivelyBack to article page